SI2206719T1 - Farmacevtski sestavek obsegajoäś 3-beta-hidroksi-17-(1-h-benzimidazol-1-il)androsta-5,16-dien - Google Patents

Farmacevtski sestavek obsegajoäś 3-beta-hidroksi-17-(1-h-benzimidazol-1-il)androsta-5,16-dien

Info

Publication number
SI2206719T1
SI2206719T1 SI200631883T SI200631883T SI2206719T1 SI 2206719 T1 SI2206719 T1 SI 2206719T1 SI 200631883 T SI200631883 T SI 200631883T SI 200631883 T SI200631883 T SI 200631883T SI 2206719 T1 SI2206719 T1 SI 2206719T1
Authority
SI
Slovenia
Prior art keywords
diene
methods
androsta
benzimidazole
beta
Prior art date
Application number
SI200631883T
Other languages
English (en)
Slovenian (sl)
Inventor
Angela Brodie
Vincent Njar
Original Assignee
University Of Maryland, Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Maryland, Baltimore filed Critical University Of Maryland, Baltimore
Publication of SI2206719T1 publication Critical patent/SI2206719T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200631883T 2005-03-02 2006-03-02 Farmacevtski sestavek obsegajoäś 3-beta-hidroksi-17-(1-h-benzimidazol-1-il)androsta-5,16-dien SI2206719T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65739005P 2005-03-02 2005-03-02
EP10150763.0A EP2206719B1 (en) 2005-03-02 2006-03-02 Pharmaceutical composition comprising 3-beta-hydroxy-17-(1-h-benzimidazole-1-yl)androsta-5,16-diene

Publications (1)

Publication Number Publication Date
SI2206719T1 true SI2206719T1 (sl) 2015-03-31

Family

ID=36941503

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200630861T SI1853619T1 (sl) 2005-03-02 2006-03-02 3-beta-hidroksi-17-(1H-benzmidazol-1-il)androsta-5,16-dien za uporabo pri zdravljenju bolezni prostate
SI200631883T SI2206719T1 (sl) 2005-03-02 2006-03-02 Farmacevtski sestavek obsegajoäś 3-beta-hidroksi-17-(1-h-benzimidazol-1-il)androsta-5,16-dien

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI200630861T SI1853619T1 (sl) 2005-03-02 2006-03-02 3-beta-hidroksi-17-(1H-benzmidazol-1-il)androsta-5,16-dien za uporabo pri zdravljenju bolezni prostate

Country Status (21)

Country Link
US (1) US7875599B2 (OSRAM)
EP (2) EP1853619B1 (OSRAM)
JP (2) JP5130453B2 (OSRAM)
KR (1) KR101380959B1 (OSRAM)
CN (2) CN101155823A (OSRAM)
AT (1) ATE482969T1 (OSRAM)
AU (1) AU2006218711B2 (OSRAM)
BR (1) BRPI0607523A2 (OSRAM)
CA (1) CA2599953C (OSRAM)
DE (1) DE602006017175D1 (OSRAM)
DK (2) DK2206719T3 (OSRAM)
EA (1) EA019560B1 (OSRAM)
ES (2) ES2528055T3 (OSRAM)
IL (3) IL185608A (OSRAM)
MX (1) MX2007010593A (OSRAM)
NZ (1) NZ561571A (OSRAM)
PL (2) PL2206719T3 (OSRAM)
PT (2) PT2206719E (OSRAM)
SI (2) SI1853619T1 (OSRAM)
WO (1) WO2006093993A1 (OSRAM)
ZA (1) ZA200708106B (OSRAM)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
DK2206719T3 (en) 2005-03-02 2015-01-26 Univ Maryland A pharmaceutical composition comprising 3-BETA-HYDROXY-17- (1-H-benzimidazol-1-yl) androsta-5, 16-DIEN
WO2008154402A2 (en) 2007-06-06 2008-12-18 University Of Maryland, Baltimore Hdac inhibitors and hormone targeted drugs for the treatment of cancer
WO2009114658A2 (en) * 2008-03-12 2009-09-17 University Of Maryland, Baltimore Androgen receptor inactivation contributes to antitumor efficacy of cyp17 inhibitors in prostate cancer
US20100048913A1 (en) * 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US20110118219A1 (en) * 2008-03-25 2011-05-19 University Of Maryland, Baltimore Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
US8785423B2 (en) * 2008-04-14 2014-07-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
EP2334686B1 (en) 2008-08-28 2019-02-27 President and Fellows of Harvard College Cortistatin analogues and syntheses therof
JP2012506906A (ja) * 2008-10-28 2012-03-22 バイオマリン ファーマシューティカル インコーポレイテッド デカヒドロ−１ｈ−インデノキノリンおよびデカヒドロ−３ｈ−シクロペンタフェナントリジノンｃｙｐ１７インヒビター
US8791095B2 (en) 2009-02-05 2014-07-29 Tokai Pharmaceuticals, Inc. Steroidal CYP17 inhibitors/antiandrogens
EP2393827B1 (en) 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
GB201114153D0 (en) * 2009-02-05 2011-10-05 Tokai Pharmaceuticals Inc Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent
WO2010149755A1 (en) 2009-06-26 2010-12-29 Novartis Ag 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
WO2011017534A2 (en) * 2009-08-07 2011-02-10 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer
CN102822190B (zh) * 2009-11-13 2016-03-30 拓凯制药公司 哺乳动物的类固醇代谢物
WO2011066582A1 (en) * 2009-11-30 2011-06-03 Harbor Biosciences, Inc. Anticancer compounds and screening method
CN103108871B (zh) 2010-09-16 2014-09-10 诺华股份有限公司 17α-羟化酶/C17,20-裂合酶抑制剂
EP2660241A3 (en) * 2010-12-16 2014-03-12 BioMarin Pharmaceutical Inc. C-17-heteroaryl steroidal compounds as inhibitors of cyp11b, cyp17, and/or cyp21
EA023064B1 (ru) 2011-04-28 2016-04-29 Новартис Аг ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
CA2841960A1 (en) * 2011-07-18 2013-01-24 Tokai Pharmaceuticals, Inc. Novel compositions and methods for treating prostate cancer
AU2012358219A1 (en) * 2011-12-22 2014-07-10 Tokai Pharmaceuticals, Inc. Methods and compositions for combination therapy using P13K/mTOR inhibitors
SG11201507093WA (en) 2013-03-14 2015-10-29 Univ Maryland Baltimore Office Of Technology Transfer Androgen receptor down-regulating agents and uses thereof
EP3514147B1 (en) * 2013-04-04 2022-08-03 University of Maryland, Baltimore Steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity
SG11201600525XA (en) * 2013-08-12 2016-02-26 Tokai Pharmaceuticals Inc Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
MY180383A (en) 2013-12-24 2020-11-28 Harvard College Cortistatin analogues and syntheses and uses thereof
CN103694299A (zh) * 2014-01-13 2014-04-02 中国药科大学 甾体类雄激素受体抑制剂、其制备方法及其医药用途
WO2016119742A1 (zh) * 2015-01-29 2016-08-04 苏州晶云药物科技有限公司 (3β)-17-(1H-苯并咪唑-1-基)雄甾-5，16-二烯-3-醇的盐及其制备方法
EP3294298A4 (en) 2015-05-08 2018-10-17 President and Fellows of Harvard College Cortistatin analogues, syntheses, and uses thereof
EP3316889A4 (en) 2015-07-01 2018-11-14 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof
WO2017066697A1 (en) 2015-10-14 2017-04-20 Dou Qingping Treatments and diagnostics for cancers
IT201600121375A1 (it) * 2016-11-30 2018-05-30 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3ß-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
IT201600083406A1 (it) * 2016-08-08 2018-02-08 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3β-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
CA3063339C (en) * 2016-08-08 2024-05-28 Industriale Chimica S.R.L. Process for the preparation of 3b-hydroxy-17-(1h-benzimidazol-1-yl)androsta-5,16-diene
US12325725B2 (en) 2018-02-13 2025-06-10 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase degraders and methods of use
CA3089588A1 (en) * 2018-02-13 2019-08-22 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase inhibitors and methods of use
US12410194B2 (en) 2019-11-26 2025-09-09 Dana-Farber Cancer Institute, Inc. Potent and selective azaindole inhibitors of CDK8 and CDK19

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA27440A (en) 1887-08-16 James T. Walsh Art of making sheet metal cans, for packing meats, fruits, vegetables, etc.
CH621803A5 (OSRAM) * 1974-08-08 1981-02-27 Siphar Sa
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5994335A (en) * 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
ES2369487T3 (es) 2003-07-29 2011-12-01 Dompe' S.P.A. Combinación farmacéutica de g-csf y plgf útil para células madre de sangre.
DK2206719T3 (en) * 2005-03-02 2015-01-26 Univ Maryland A pharmaceutical composition comprising 3-BETA-HYDROXY-17- (1-H-benzimidazol-1-yl) androsta-5, 16-DIEN

Also Published As

Publication number Publication date
IL210480A0 (en) 2011-03-31
PL1853619T3 (pl) 2011-03-31
NZ561571A (en) 2009-09-25
ATE482969T1 (de) 2010-10-15
IL185608A0 (en) 2008-01-06
JP2012255026A (ja) 2012-12-27
EA019560B1 (ru) 2014-04-30
EP1853619B1 (en) 2010-09-29
EA200701872A1 (ru) 2008-06-30
ZA200708106B (en) 2008-12-31
KR20070120119A (ko) 2007-12-21
HK1115387A1 (en) 2008-11-28
IL210480A (en) 2015-06-30
CN101155823A (zh) 2008-04-02
PL2206719T3 (pl) 2015-03-31
IL210478A0 (en) 2011-03-31
WO2006093993A1 (en) 2006-09-08
JP2008536807A (ja) 2008-09-11
ES2353413T3 (es) 2011-03-01
CN103349664A (zh) 2013-10-16
SI1853619T1 (sl) 2011-01-31
JP5130453B2 (ja) 2013-01-30
PT2206719E (pt) 2015-02-05
DE602006017175D1 (de) 2010-11-11
CA2599953A1 (en) 2006-09-08
BRPI0607523A2 (pt) 2009-09-08
KR101380959B1 (ko) 2014-04-04
CA2599953C (en) 2013-08-13
MX2007010593A (es) 2008-02-20
EP1853619A1 (en) 2007-11-14
JP5613206B2 (ja) 2014-10-22
IL185608A (en) 2016-06-30
AU2006218711B2 (en) 2010-11-11
DK1853619T3 (da) 2011-01-10
US20080280864A1 (en) 2008-11-13
AU2006218711A1 (en) 2006-09-08
EP2206719A3 (en) 2011-01-05
US7875599B2 (en) 2011-01-25
EP2206719B1 (en) 2014-10-22
DK2206719T3 (en) 2015-01-26
PT1853619E (pt) 2011-01-03
EP1853619A4 (en) 2009-08-26
AU2006218711A2 (en) 2006-09-08
ES2528055T3 (es) 2015-02-03
EP2206719A2 (en) 2010-07-14

Similar Documents

Publication Publication Date Title
SI2206719T1 (sl) Farmacevtski sestavek obsegajoäś 3-beta-hidroksi-17-(1-h-benzimidazol-1-il)androsta-5,16-dien
PT1353672E (pt) Síntese da 4-amino talidomida enantiómeros
EP2966065A3 (en) Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
WO2007087548A3 (en) Chemical compounds
PT1934174E (pt) Azetidinas como inibidores de mek para o tratamento de doenças proliferativas
MX2009003876A (es) Uso de compuestos de espiro-oxindol como agentes terapeuticos.
WO2009120565A3 (en) Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
NO20076319L (no) Farmasoytiske sammensetninger av et neuroaktivt steroid og anvendelse derav
AU2010210422A8 (en) Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
GEP20115213B (en) Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
WO2005077968A3 (en) 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity
WO2005103010A3 (en) Pyrazole derivatives useful for the treatment of cancer
WO2008011539A3 (en) Anesthetic compounds
CY1115910T1 (el) ΦΑΡΜΑΚΕΥΤΙΚΗ ΣΥΝΘΕΣΗ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΕΙ 3-BETA-HYDROXY-17-(l-HBENZIMIDAZOLE-1-YL)ANDROSΤΑ-5,16-DIENE
WO2007045060A8 (en) Pharmaceutical compositions containing erythrine mulungu derivatives and processes for their production
UA93198C2 (ru) Производные пиразола, способ их получения, их применения, фармацевтическая композиция (варианты) и способ лечения злокачественного новообразования (варианты)
TW200603812A (en) D-homo-17-chlor-16(17)-ene steroids
TW200740442A (en) Therapeutic agent for hypertension
UA96742C2 (en) Mek inhibitors and use thereof